|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0031327,
umls-concept:C0036043,
umls-concept:C0178602,
umls-concept:C0205314,
umls-concept:C0205390,
umls-concept:C0376545,
umls-concept:C0679622,
umls-concept:C1443643,
umls-concept:C1709429,
umls-concept:C2001856,
umls-concept:C2603343
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2009-11-13
|
|
pubmed:abstractText |
Carfilzomib (formerly PR-171) is a novel proteasome inhibitor of the epoxyketone class that is selective and structurally distinct from bortezomib. Proteasome inhibition by carfilzomib is mechanistically irreversible. Consequently, proteasome inhibition is more sustained with carfilzomib than with bortezomib.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7085-91
|
|
pubmed:meshHeading |
pubmed-meshheading:19903785-Adult,
pubmed-meshheading:19903785-Aged,
pubmed-meshheading:19903785-Aged, 80 and over,
pubmed-meshheading:19903785-Antineoplastic Agents,
pubmed-meshheading:19903785-Dose-Response Relationship, Drug,
pubmed-meshheading:19903785-Female,
pubmed-meshheading:19903785-Hematologic Neoplasms,
pubmed-meshheading:19903785-Humans,
pubmed-meshheading:19903785-Male,
pubmed-meshheading:19903785-Maximum Tolerated Dose,
pubmed-meshheading:19903785-Middle Aged,
pubmed-meshheading:19903785-Oligopeptides,
pubmed-meshheading:19903785-Protease Inhibitors,
pubmed-meshheading:19903785-Proteasome Endopeptidase Complex,
pubmed-meshheading:19903785-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.
|
|
pubmed:affiliation |
NYU Cancer Institute, NYU Langone Medical Center, 522 First Ave., Smilow 1101, New York, NY, USA. owen.o'connor@nyumc.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
